Background: The morbidity and mortality of acute myocardial infarction are on the rise, and the efficacy of conventional treatment is limited. Shexiang Baoxin Pill is a kind of proprietary Chinese medicine, which has been widely used in the treatment of acute myocardial infarction in China, and has certain advantages. At present, there is a lack of strict randomized controlled trials to verify the efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction. Therefore, the purpose of this randomized controlled trial is to evaluate the clinical efficacy of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction.
Methods: This is a prospective randomized controlled trial to study the efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction. It is approved by the Clinical Research Society of our hospital. According to 1:1, the patients will be randomly divided into observation group (Shexiang Baoxin Pill combined with Western medicine group) and control group (routine Western medicine group). The patients in the 2 groups will be treated continuously for 4 weeks and followed up for 3 months. Pay attention to its curative effect index and safety index. The observation indexes included total effective rate of improvement of cardiac function, left ventricular ejection fraction (LVEF), endothelin (ET), nitric oxide (NO) level, interleukin-6 (IL--6), adverse reactions, and so on. We will analyze the structure by SPSS version 19.0.
Discussion: This study will evaluate the efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction. The results of this experiment will provide clinical basis for Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction.
Trial Registration: OSF Registration number: DOI 10.17605/OSF.IO/PYJTK.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837911 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000024246 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Shexiang Baoxin Pill (MUSKARDIA) in Patients with Stable Coronary Artery Disease Across Different Weight Subgroups.
J Ethnopharmacol
January 2025
Department of Cardiovascular Internal Medicine, Zhongshan Hospital, Fudan University, Shanghai 200000, China.
Ethnopharmacological Relevance: Shexiang Baoxin Pill (MUSKARDIA), a traditional Chinese patent medicine, plays a crucial role in both preventing and treating diverse cardiovascular diseases, including coronary heart disease, myocardial infarction (MI), and heart failure. Preclinical research has demonstrated that the cardioprotective effects of MUSKARDIA are achieved through multiple pathways, such as enhancing coronary artery dilation, fostering new blood vessel growth, reducing inflammation and oxidative stress, improving lipid metabolism, and protecting vascular endothelium.
Aim Of The Study: This subgroup analysis aimed to evaluate the efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) plus optimal medical therapy (OMT) across different weight categories in treating stable coronary artery disease (CAD).
Integrated metabolomics and network pharmacology to reveal the mechanisms of Shexiang Baoxin pill against atherosclerosis.
Phytomedicine
December 2024
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China; Department of Cardiology, The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China. Electronic address:
Background: Atherosclerosis is a disease marked by the development of lipid lesions within the endothelium and continues to be a prominent contributor to global mortality. Shexiang Baoxin pill (SBP) has been employed in the management of numerous cardiovascular diseases, but the complex mechanisms by which it operates remain obscure. This research was conducted to determine the potential impact of SBP on atherosclerosis and the underlying regulatory mechanism involved.
View Article and Find Full Text PDFComparative efficacy of eight oral Chinese patent medicines for dilated cardiomyopathy with heart failure: a Bayesian network meta-analysis.
Syst Rev
August 2024
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Chinese patent medicines (CPMs) are widely used in China as an adjuvant treatment in dilated cardiomyopathy with heart failure (DCM-HF). However, comprehensive and systematic evidence supporting the beneficial effects of CPMs combined with current complementary and alternative medicine (CAM) treatments against DCM-HF was limited. This network meta-analysis (NMA) aimed to assess and rank the relative efficacy of eight different CPMs for DCM-HF.
View Article and Find Full Text PDF[Network Meta-analysis of Chinese patent medicines in treatment of chronic pulmonary heart disease].
Zhongguo Zhong Yao Za Zhi
July 2024
Department of Cardiovascular Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
Article Synopsis
- A network meta-analysis was conducted to evaluate the effectiveness and safety of various Chinese patent medicines for treating chronic pulmonary heart disease, analyzing data from numerous databases including CNKI, PubMed, and Cochrane Library, up to December 2023.
- The analysis included 95 randomized controlled trials (RCTs) with a total of 8,787 patients and assessed multiple Chinese patent medicines, focusing on metrics like cardiac function, forced expiratory volume, and partial pressure of gases in the blood.
- Top-performing treatments combined Chinese medicines with conventional western medicines, including Wenxin Granules, Tongxinluo Capsules, and Qishen Yiqi Dropping Pills for overall efficacy and improvements in respiratory function.
The antidepressant effect of Shexiang Baoxin Pills on myocardial infarction rats with depression may be achieved through the inhibition of the NLRP3 inflammasome pathway.
Brain Behav
July 2024
Department of Cardiovascular Medicine, Affiliated Renhe Hospital of China Three Gorges University, Yichang, China.
Background: Patients with myocardial infarction (MI) frequently experience a heightened incidence of depression, thereby increasing the risk of adverse cardiovascular events. Consequently, early detection and intervention in depressive symptoms among patients with MI are imperative. Shexiang Baoxin Pills (SBP), a Chinese patent medicine employed for the treatment of MI, exhibits diverse mechanisms targeting this condition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!